| Literature DB >> 27895634 |
Divakar Sharma1, Manju Lata1, Rananjay Singh1, Nirmala Deo1, Krishnamurthy Venkatesan1, Deepa Bisht1.
Abstract
Emergence of extensively drug resistant tuberculosis (XDR-TB) is the consequence of the failure of second line TB treatment. Aminoglycosides are the important second line anti-TB drugs used to treat the multi drug resistant tuberculosis (MDR-TB). Main known mechanism of action of aminoglycosides is to inhibit the protein synthesis by inhibiting the normal functioning of ribosome. Primary target of aminoglycosides are the ribosomal RNA and its associated proteins. Various mechanisms have been proposed for aminoglycosides resistance but still some are unsolved. As proteins are involved in most of the biological processes, these act as a potential diagnostic markers and drug targets. In the present study we analyzed the purely cytosolic proteome of amikacin (AK) and kanamycin (KM) resistant Mycobacterium tuberculosis isolates by proteomic and bioinformatic approaches. Twenty protein spots were found to have over expressed in resistant isolates and were identified. Among these Rv3208A, Rv2623, Rv1360, Rv2140c, Rv1636, and Rv2185c are six proteins with unknown functions or undefined role. Docking results showed that AK and KM binds to the conserved domain (DUF, USP-A, Luciferase, PEBP and Polyketidecyclase/dehydrase domain) of these hypothetical proteins and over expression of these proteins might neutralize/modulate the effect of drug molecules. TBPred and GPS-PUP predicted cytoplasmic nature and potential pupylation sites within these identified proteins, respectively. String analysis also suggested that over expressed proteins along with their interactive partners might be involved in aminoglycosides resistance. Cumulative effect of these over expressed proteins could be involved in AK and KM resistance by mitigating the toxicity, repression of drug target and neutralizing affect. These findings need further exploitation for the expansion of newer therapeutics or diagnostic markers against AK and KM resistance so that an extreme condition like XDR-TB can be prevented.Entities:
Keywords: Mycobacterium tuberculosis; amikacin; bioinformatic tools; cytosolic proteome; kanamycin; resistance
Year: 2016 PMID: 27895634 PMCID: PMC5108770 DOI: 10.3389/fmicb.2016.01816
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Figure 1Composite images of 2DE profile of cytosolic proteome of .
Details of proteins identified by mass spectrometry.
| D 1 | Trigger factor | 78 | 50586 | 4.47 | 33 | Rv2462c | 1: 3.80 | 2 | |
| D 2 | 3-oxoacyl-[acyl-carrier-protein] synthase II | 133 | 44250 | 5.27 | 35 | Rv2246 | 1: 2.50 | 7 | |
| D 3 | 3-ketoacyl-ACP reductase | 198 | 46988 | 5.86 | 62 | Rv0242c | 1: 2.60 | 7 | |
| D 4 | Transcriptional regulator MoxR1 | 117 | 40752 | 5.96 | 36 | Rv1479 | 1: 2.20 | 4 | |
| D 5 | Fructose-bisphosphate aldolase | 74 | 36522 | 5.49 | 29 | Rv0363c | 1: 3.50 | 1 | |
| D 6 | Universal stress protein | 70 | 31632 | 5.46 | 41 | Rv2623 | 1: 1.83 | 5 | |
| D 7 | Uncharacterized Protein | 68 | 37570 | 6.38 | 27 | Rv1360 | 1: 2.50 | 1 | |
| D 8 | Alkyl hydroperoxide reductase subunit C | 142 | 21553 | 4.50 | 83 | Rv2428 | 1: 2.90 | 5 | |
| D 9 | Enoyl-coA hydratase | 79 | 24281 | 5.52 | 57 | Rv0632c | 1: 3.98 | 7 | |
| D 10 | Adenylate kinase | 168 | 20113 | 5.02 | 72 | Rv0733 | 1: 3.60 | 1 | |
| D 11 | Single stranded DNA-binding protein | 86 | 17343 | 5.12 | 40 | Rv0054 | 1: 2.10 | 3 | |
| D 12 | Peptidalprolyl isomerase | 86 | 19271 | 5.80 | 54 | Rv0009 | 1: 2.80 | 3 | |
| D 13 | Peptidalprolyl isomerase | 89 | 19271 | 5.80 | 54 | Rv0009 | 1: 3.10 | 3 | |
| D 14 | Beta carbonic anhydrase 1 | 117 | 18177 | 5.48 | 45% | Rv1284 | 1: 2.81 | 1 | |
| D 15 | UPF0098 protein | 137 | 18622 | 5.41 | 55 | Rv2140c | 1: 1.80 | 6,1 | |
| D16 | Hypothetical protein | 74 | 16314 | 4.75 | 45 | Rv2185c | 1: 1.90 | 6,7 | |
| D17 | Universal stress protein | 69 | 15303 | 5.51 | 44 | Rv1636 | 1: 1.72 | 5 | |
| D 18 | Alpha-crystallin | 63 | 16217 | 5.00 | 48 | Rv2031c | 1: 1.83 | 5 | |
| D 19 | Probable cold shock protein A | 51 | 7366 | 5.17 | 83 | Rv3648c | 1: 2.60 | 5 | |
| D 20 | Conserved Hypothetical protein | 134 | 9884 | 4.86 | 90 | Rv3208A | 1: 1.90 | 6 |
1, intermediary metabolism and respiration; 2, cell wall and cell processes; 3, information pathways; 4, regulatory proteins; 5, virulence, detoxification adaptation; 6, conserved hypothetical; 7, lipid metabolism.
Note on functional category.
Prediction of classes of these identified proteins by TBpred server.
| Rv2462c | 3.108 | 1.355 | Cytoplasmic |
| Rv2246 | 0.927 | 0.949 | Cytoplasmic |
| Rv0242c | 0.704 | −0.009 | Integral MP/Cytoplasmic |
| Rv1479 | 2.402 | 0.057 | Integral MP |
| Rv0363c | 2.062 | 2.189 | Cytoplasmic |
| Rv2623 | 1.061 | 0.549 | Cytoplasmic/Integral MP |
| Rv1360 | 1.226 | 0.616 | Cytoplasmic |
| Rv2428 | 0.417 | 0.460 | Cytoplasmic |
| Rv0632c | 0.676 | 0.482 | Integral MP/Cytoplasmic |
| Rv0733 | 4.242 | 2.154 | Cytoplasmic |
| Rv0054 | 0.319 | −0.496 | Attached to Membrane by Lipid Anchor/Secretory |
| Rv0009 | 0.553 | 0.223 | Attached to Membrane by Lipid Anchor |
| Rv1284 | 1.762 | 1.515 | Cytoplasmic |
| Rv2140c | 0.110 | 0.081 | Integral MP/Cytoplasmic |
| Rv2185c | 3.738 | 2.543 | Cytoplasmic |
| Rv1636 | 3.225 | 0.341 | Cytoplasmic |
| Rv2031c | 2.524 | 2.397 | Cytoplasmic |
| Rv3648c | 0.430 | 1.765 | Integral MP/Cytoplasmic |
| Rv3208A | 2.287 | 1.209 | Cytoplasmic |
Modeling, docking parameters and analysis of interacting amino acids to drugs.
| Rv3208A | 0.37 ± 0.12 | 10.5 ± 4.6Å | AK | −24.82 | 18.86 | 11.20 | −8.52 | 45–50, 69–72,74, 90 | AK binds to conserved domain (DUF3107) of unknown function |
| Rv3208A | 0.37 ± 0.12 | 10.5 ± 4.6Å | KM | −26.40 | −16.16 | 3.07 | −6.03 | 26, 30, 40, 42, 52, 53, 86, 88, 89 | KM binds to conserved domain (DUF3107) of unknown function |
| Rv2623 | 0.95 ± 0.05 | 2.9 ± 2.1Å | AK | −55.14 | −23.38 | 7.83 | −17.58 | 167, 198, 261–263, 267–269, 272, 274–278 | AK binds into central cavity of conserved USP-A domain |
| Rv2623 | 0.95 ± 0.05 | 2.9 ± 2.1Å | KM | −53.96 | −23.57 | 2.53 | −13.96 | 167, 198, 245, 262, 263, 265, 267–269, 272, 274–277 | KM also binds into central cavity of conserved USP-A domain |
| Rv1360 | 0.88 ± 0.07 | 4.0 ± 2.7Å | AK | −51.96 | −21.77 | 6.16 | −15.20 | 99,110, 170–172, 174, 175, 188, 189, 196, 199, 252, 253, 255, 257, 258, 295 | AK interact to conserved Luciferase like domain of uncharacterized protein |
| Rv1360 | 0.88 ± 0.07 | 4.0 ± 2.7Å | KM | −48.15 | −21.32 | 3.57 | −12.25 | 63, 64, 96, 98–00, 168–70, 174, 186–188, 223, 252, 253, 255 | KM also interact to conserved Luciferase like domain of of uncharacterized protein |
| Rv2140c | 0.97 ± 0.05 | 1.7 ± 1.4Å | AK | −41.65 | −17.05 | 5.19 | −15.42 | 7, 11, 12, 67, 75, 78, 153, 156, 157, 160 | AK binds to PEBP domain of hypothetical UPF0098 protein |
| Rv2140c | 0.97 ± 0.05 | 1.7 ± 1.4Å | KM | −42.41 | −17.98 | 5.47 | −14.14 | 7, 8, 11, 12, 67, 69, 75, 78, 153, 156, 157, 160, 166 | KM binds to PEBP domain of hypothetical UPF0098 protein |
| Rv1636 | 0.80 ± 0.09 | 3.4 ± 2.4Å | AK | −26.95 | −13.46 | 0.95 | −9.50 | 114, 115, 121–125, 144–146 | AK binds to binds to conserved USP-A domain of uncharacterized protein |
| Rv1636 | 0.80 ± 0.09 | 3.4 ± 2.4Å | KM | −33.03 | −14.91 | 7.87 | −11.76 | 41, 42, 44, 94, 115–118, 123, 126–128 | KM binds to binds to conserved USP-A domain of uncharacterized protein |
| Rv2185c | 0.82 ± 0.09 | 3.2 ± 2.3Å | AK | −45.57 | −23.23 | 14.30 | −13.91 | 28, 32, 35, 50, 54, 63, 65, 67, 69, 80, 88, 95, 108, 110, 123, 127, 130, 131, 134, 138 | AK binds to conserved Polyketide cyclase/ dehydrase domain of hypothetical protein |
| Rv2185c | 0.82 ± 0.09 | 3.2 ± 2.3Å | KM | −41.48 | −17.75 | 2.17 | −10.55 | 32, 34, 35, 54, 56, 63, 65, 80, 91, 95, 108, 110, 112, 123, 127, 130, 131, 134 | KM binds to conserved Polyketide cyclase/ dehydrase domain of hypothetical protein |
Figure 23D model of hypothetical proteins showing docking with AK and KM. (A1,A2) shows molecular docking of Rv3208A with AM (blue) and KM (red), respectively, yellow color shows interacting residues of DUF3107 domain. (B1,B2) shows molecular docking of Rv2623 with AM (blue) and KM (red), respectively, yellow color show interacting residues of USP-A domain.
Figure 33D model of hypothetical proteins showing docking with AK and KM. (C1,C2) shows docking of Rv1360 with AM (blue) and KM (red), respectively, yellow color shows interacting residues of luciferase like domain. (D1,D2) shows docking of Rv2140c with AM (blue) and KM (red), respectively, yellow color shows interacting residues of conserved PEBP domain of hypothetical UPF0098 protein.
Figure 43D model of hypothetical proteins showing docking with AK and KM. (E1,E2) shows docking of Rv1636 with AM (blue) and KM (red), respectively, yellow color shows interacting residues of conserved USP-A domain, (F1,F2) shows docking of Rv2185c with AM (blue) and KM (red), respectively, yellow color shows interacting residues of conserved Polyketide cyclase/dehydrase domain of hypothetical protein.
Predicted/identified pupylation sites within identified proteins.
| Rv2462c | 2 | ******V | 2.614 | 2.452 |
| 33 | PDFQRAY | 3.394 | 2.452 | |
| 274 | SDQVRQA | 2.669 | 2.452 | |
| 439 | DTSEFFG | 2.677 | 2.452 | |
| Rv2246 | 54 | TDAETTW | 2.543 | 2.452 |
| 164 | VSPLTVQ | 2.795 | 2.452 | |
| Rv0242c | 100 | ITEPAGL | 2.591 | 2.452 |
| 150 | GFTRSLG | 2.472 | 2.452 | |
| 168 | VYLSPDA | 3.827 | 2.452 | |
| 381 | LAPGLAA | 3.323 | 2.452 | |
| Rv1479 | 71 | MLVGLLS | 2.646 | 2.452 |
| Rv0363c | 149 | AIAQELL | 3.669 | 2.452 |
| 155 | LKAAAAA | 3.016 | 2.452 | |
| 189 | TSPEDFE | 3.165 | 2.452 | |
| 318 | YDPRSYL | 2.52 | 2.452 | |
| Rv2623 | 35 | ARDAELR | 3.63 | 2.452 |
| Rv2428 | 25 | LIGGDLS | 4.071 | 2.452 |
| 70 | TEIAAFS | 3.11 | 2.452 | |
| 192 | LDAGELL | 6.024 | 2.452 | |
| Rv0733 | 23 | QAVKLAE | 4.26 | 2.452 |
| 94 | PRSVEQA | 5.756 | 2.452 | |
| 181 | RALRALG | 5.866 | 2.452 | |
| Rv0054 | 84 | VIVSGRL | 2.866 | 2.452 |
| 95 | FETREGE | 2.945 | 2.452 | |
| Rv0009 | 133 | QFFITVG | 2.646 | 2.452 |
| 161 | RVVEAIS | 2.772 | 2.452 | |
| Rv2140c | 133 | QFFITVG | 2.646 | 2.452 |
| Rv2185c | 89 | LESSSLL | 3.079 | 2.452 |
| 136 | RLIDGAL | 3.236 | 2.452 | |
| 139 | DGALKDL | 2.803 | 2.452 | |
| 140 | GALKDL | 3.496 | 2.452 | |
| Rv2031c | 64 | LPGVDPD | 2.669 | 2.452 |
| 85 | KAERTEQ | 2.748 | 2.452 | |
| 114 | GADEDDI | 3.386 | 2.452 | |
| 119 | DIKATYD | 2.913 | 2.452 | |
| 132 | SVAVSEG | 3.433 | 2.452 | |
| Rv3648c | 47 | RTLEENQ | 3.236 | 2.452 |
| 57 | FEIGHSP | 2.591 | 2.452 | |
| Rv3208A | 85 | AAAGSAG | 4.126 | 2.452 |
Bold letter “.
.
Figure 5STRING analysis reveals the interaction partners of the over expressed proteins which showed that over expressed proteins interacted to proteins of the similar functional categories except the hypothetical proteins.